← boardnext 2026-08
NCNA
NuCana plcdistress 2/10 · well-funded / low risk$1.360%today-89% from 52w high
Oncology 2
Lead: Advanced Cancer · target PD-1
Revenue
pre-revenue
Liquidity
$22M
Runway
2.9 yrs
Shares 1y
0%
Price & events
-57.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+2.3%
1W
-21.4%
1M
-36.7%
3M
-58.3%
6M
-87.2%
1Y
-99.8%
2Y
-100.0%
5Y
-100.0%
All
Overview
- Market Cap
- $28.30B
- Volume
- 5.90K
- 52 Week Range
- $1.24 – $12.00
- Total Shares
- 20.81B
- Float Shares
- 4.16M
- Short %
- 2.78%
- % Held by Insiders
- 0.00%
- % Held by Institutions
- 1.38%
- RVOL
- 0.10x
- Beta
- 2.24
Pipeline stages · 2 programs
NUC-7738, PembrolizumabPD-1
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Fosifloxuridine Nafalbenamide, Leucovorin, PembrolizumabPD-1
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-08 Estimated 50% readout ~2026-09-15 | Phase 1/2 | NUC-7738, Pembrolizumab | Advanced Cancer, Lymphoma, Solid Tumor, Melanoma | 135 | recruiting |
| 2025-05-30 | Phase 1/2 | Fosifloxuridine Nafalbenamide, Leucovorin, Pembrolizumab | Advanced Cancer, Advanced Solid Tumor, Neoplasm Malignant, Metastatic Cancer, Melanoma, Classical Hodgkin Lymphoma, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma, Subungual Squamous Cell Carcinoma, Oesophageal Carcinoma, MSI-H Colorectal Cancer, Gastric Cancer, Triple Negative Breast Cancer, Endometrial Carcinoma, Pleural Mesothelioma | 19 | terminated |
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2024-08-19OppenheimerOutperform
- 2024-07-23OppenheimerOutperform
- 2024-07-22OppenheimerOutperform
Competitors — PD-1
- REGNREGENERON PHARMACEUTICALS, INC.$60.4B · D2
- BEIGFBeOne Medicines Ltd.$31.7B · D1
- EXELEXELIXIS, INC.$13.8B · D0
- TNGXTango Therapeutics, Inc.$4.0B · D5
- IOVAIOVANCE BIOTHERAPEUTICS, INC.$2.3B · D4
- CGEMCullinan Therapeutics, Inc.$1.1B · D1
- REPLReplimune Group, Inc.$906M · D2
- ALXOALX ONCOLOGY HOLDINGS INC$262M · D5
- BCABBioAtla, Inc.$107M · D8
- IOBTQIO Biotech, Inc.$71,949 · D5
Recent news
- 2026-07-22NuCana stock rally: Technical outlook - Traders Union
- 2026-07-20NuCana shares technical analysis: $1.21 support under pressure - Traders Union
- 2026-07-15NuCana stock rally gains pace. Will NCNA sustain growth? - Traders Union
- 2026-07-14Why is NuCana stock rising today? Strong intraday buying limits further downside - Traders Union
- 2026-07-13NuCana shares technical analysis: Support test after momentum weakens - Traders Union
- 2026-07-10NuCana plc (NCNA) Shows Resilience: Modest Uptick Amid Biotech Volatility - Retracement Entry - dars.gov.et
- 2026-07-10NuCana shares technical analysis: Short-term momentum favors sellers - Traders Union
- 2026-07-10Why is NuCana stock up 4.4% today? - Traders Union
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.